Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE with Sintilimab and Bevacizumab Biosimilar in Advanced HCC
NCT04796025Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2021
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
sintilimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04796025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04796025.